Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Likely To Play Up Saphris' Safety In Q4 Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.
Advertisement

Related Content

Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
What Fred Said: Schering-Plough's Hassan On Life In Big Pharma
What Fred Said: Schering-Plough's Hassan Shares His Views on Life in Big Pharma
Lurasidone Beats Placebo In Phase III, But Zyprexa Arm Could Confound
Dainippon's Phase III Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa
Acorda's MS Drug Amaya Panel Review Leaves Little Time To React
Atypical Antipsychotic Market Snapshot: Making Way For Three New Drugs
Abigail Alliance Presses For Access To Drugs With Troubled Regulatory Pasts
Abigail Alliance Presses For Access To Drugs With Troubled Regulatory Pasts
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion

Topics

Advertisement
UsernamePublicRestriction

Register

PS069844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel